Browsing by Author "Ma, J."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Eudesmane-Type Sesquiterpenes from Curcuma phaeocaulis and Their Inhibitory Activities on Nitric Oxide Production in RAW 264.7 Cells(European Journal of Organic Chemistry, 2014-09) Liu, Y.; Ma, J.; Wang, Y.; Donkor, P.O.; Li, Q.; Gao, S.; Hou, Y.; Xu, Y.; Cui, J.; Ding, L.; Zhao, F.; Kang, N.; Chen, L.; Qiu, F.Eight eudesmane-type sesquiterpenes - phaeusmanes A-H (1-8) - isolated for the first time in this work, and four others (9-12) isolated for the first time from plants in this work, together with fourteen known eudesmane derivatives, were isolated from the rhizomes of Curcuma phaeocaulis. Their structures were elucidated by 1D and 2D NMR and CD spectroscopy and HRMS. Compound 8 is the first example of a nitrogen-containing eudesmane-type sesquiterpene isolated from the genus Curcuma. Furthermore, inhibitory effects of the isolated compounds on NO production in lipopolysaccharide-activated macrophages were evaluated. Compounds 1, 6, 10, 19, 22, and 24 showed strong inhibitory activities on NO production with IC50 values of 3.2, 4.8, 1.2, 0.8, 3.8, and 0.8 μM, respectively. Preliminary structure-activity relationships for these compounds are proposed. A possible biogenetic pathway for nitrogen-containing eudesmane-type sesquiterpene 8 is postulated. Eight new sesquiterpenes (phaeusmanes A-H), together with eighteen known analogues, were isolated from the rhizomes of Curcuma phaeocaulis. Their complete structures were elucidated by NMR, MS, and CD spectroscopy. The NO inhibitory effects of the isolates are presented. A possible biogenetic pathway for N-containing eudesmane-type sesquiterpene 8 is postulated. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.Item A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate(nature, 2021) Sanchez-Felipe, L.; Vercruysse, T.; Sharma, S.; Ma, J.; Lemmens, V.; Looveren, D.V.; Javarappa, M.P.A.; Boudewijns, R.; Malengier-Devlies, B.; Liesenborghs, L.; Kaptein, S.J.F.; De Keyzer, C.; Bervoets, L.; Debaveye, S.; Rasulova, M.; Seldeslachts, L.; Li, L.; Jansen, S.; Yakass, M.B.; Verstrepen, B.E.; Böszörményi, K.P.; Kiemenyi-Kayere, G.; van Driel, N.; Quaye, O.; Zhang, X.; ter Horst, S.; Mishra, N.; Deboutte, W.; Matthijnssens, J.; Coelmont, L.; Vandermeulen, C.; Heylen, E.; Vergote, V.; Schols, D.; Wang, Z.; Bogers, W.; Kuiken, T.; Verschoor, E.; Cawthorne, C.; Van Laere, K.; Opdenakker, G.; Velde, G.V.; Weynand, B.; Teuwen, D.E.; Matthys, P.; Neyts, J.; Thibaut, H.J.; Dallmeier, K.The expanding pandemic of coronavirus disease 2019 (COVID-19) requires the development of safe, efcacious and fast-acting vaccines. Several vaccine platforms are being leveraged for a rapid emergency response1 Here we describe the development of a candidate vaccine (YF-S0) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses live-attenuated yellow fever 17D (YF17D) vaccine as a vector to express a noncleavable prefusion form of the SARS-CoV-2 spike antigen. We assess vaccine safety, immunogenicity and efcacy in several animal models. YF-S0 has an excellent safety profle and induces high levels of SARS-CoV-2 neutralizing antibodies in hamsters (Mesocricetus auratus), mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis), and—concomitantly—protective immunity against yellow fever virus. Humoral immunity is complemented by a cellular immune response with favourable T helper 1 polarization, as profled in mice. In a hamster model2 and in macaques, YF-S0 prevents infection with SARS-CoV-2. Moreover, a single dose conferred protection from lung disease in most of the vaccinated hamsters within as little as 10 days. Taken together, the quality of the immune responses triggered and the rapid kinetics by which protective immunity can be attained after a single dose warrant further development of this potent SARS-CoV-2 vaccine candidate.